|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4271164A
(en)
*
|
1979-04-16 |
1981-06-02 |
Warner-Lambert Company |
6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
|
|
KR890002631B1
(ko)
|
1984-10-04 |
1989-07-21 |
몬산토 캄파니 |
생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
GB9420168D0
(en)
*
|
1994-10-06 |
1994-11-23 |
Boots Co Plc |
Therapeutic agents
|
|
WO1997001331A2
(fr)
|
1995-06-27 |
1997-01-16 |
Takeda Chemical Industries, Ltd. |
Production de preparations a liberation prolongee
|
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
|
CA2217134A1
(fr)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Formulation a liberation-retard
|
|
ES2221019T3
(es)
|
1996-10-31 |
2004-12-16 |
Takeda Chemical Industries, Ltd. |
Preparacion de liberacion mantenida.
|
|
ZA9711385B
(en)
|
1996-12-20 |
1999-06-18 |
Takeda Chemical Industries Ltd |
Method of producing a sustained-release preparation
|
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
|
JP2002509536A
(ja)
|
1997-07-01 |
2002-03-26 |
ワーナー−ランバート・カンパニー |
２−（４−ブロモ又は４−ヨードフェニルアミノ）安息香酸誘導体及びｍｅｋ阻害物質としてのそれらの使用
|
|
AU742999B2
(en)
*
|
1997-08-20 |
2002-01-17 |
Warner-Lambert Company |
Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
|
|
JP2910748B2
(ja)
|
1997-11-12 |
1999-06-23 |
日本電気株式会社 |
異質同軸部材の端面の球状加工装置及びその方法
|
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
|
GEP20032999B
(en)
|
1999-01-13 |
2003-06-25 |
Warner Lambert Co |
1-Heterocycle Substituted Diarylamines
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
TWI343377B
(en)
|
2002-03-13 |
2011-06-11 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
AU2003225161A1
(en)
|
2002-04-24 |
2003-11-10 |
Koo, Han-Mo |
Enhancement of human epidermal melanogenesis
|
|
CA2492112A1
(fr)
*
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alcoxy-pyrido-pyrimidines utilisees comme inhibiteurs de la map kinase p-38
|
|
NZ547481A
(en)
|
2003-11-19 |
2009-12-24 |
Array Biopharma Inc |
Heterocyclic inhibitors of mek and methods of use thereof
|
|
JP2008503446A
(ja)
|
2004-05-06 |
2008-02-07 |
プレキシコン，インコーポレーテッド |
Ｐｄｅ４ｂ阻害剤及びその使用
|
|
PT2298768E
(pt)
|
2004-06-11 |
2012-12-05 |
Japan Tobacco Inc |
Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
|
|
US7674907B2
(en)
|
2004-07-23 |
2010-03-09 |
Amgen Inc. |
Furanopyridine derivatives and methods of use
|
|
AR051248A1
(es)
|
2004-10-20 |
2007-01-03 |
Applied Research Systems |
Derivados de 3-arilamino piridina
|
|
MX2007009335A
(es)
|
2005-02-02 |
2007-12-07 |
Nexgenix Pharmaceuticals L L C |
Tratamiento local de neurofibromas.
|
|
DK2395004T3
(en)
|
2005-06-22 |
2016-03-21 |
Plexxikon Inc |
Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
|
|
CN103524392B
(zh)
|
2005-10-07 |
2018-06-01 |
埃克塞利希斯股份有限公司 |
作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
WO2007123939A2
(fr)
|
2006-04-19 |
2007-11-01 |
Laboratoires Serono S.A. |
Nouveaux arylamino n-hétéraryles en tant qu'inhibiteurs de mek
|
|
GB0616214D0
(en)
|
2006-08-15 |
2006-09-27 |
Ucb Sa |
Therapeutic Agents
|
|
CA2658725A1
(fr)
|
2006-08-16 |
2008-02-21 |
Exelixis, Inc. |
Procedes d'utilisation de modulateurs pi3k etmek
|
|
WO2008024725A1
(fr)
|
2006-08-21 |
2008-02-28 |
Genentech, Inc. |
Composés aza-benzofuranyle et leurs procédés d'utilisation
|
|
EP2069359B1
(fr)
|
2006-08-21 |
2014-11-12 |
Genentech, Inc. |
Composés aza-benzothiophényle et leurs procédés d'utilisation
|
|
JP5432716B2
(ja)
|
2006-10-17 |
2014-03-05 |
ヌーボ リサーチ インコーポレイテッド |
ジクロフェナクゲル
|
|
EP2113500A1
(fr)
|
2006-10-31 |
2009-11-04 |
Takeda Pharmaceutical Company Limited |
Inhibitêur du kinàse MAPK/ERK
|
|
CA2672327A1
(fr)
|
2006-11-30 |
2008-06-05 |
Genentech, Inc. |
Composes azaindolyliques et procedes d'utilisation de ceux-ci
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
CL2008001373A1
(es)
|
2007-05-11 |
2008-11-21 |
Bayer Schering Pharma Ag |
Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
|
|
WO2008148034A1
(fr)
|
2007-05-25 |
2008-12-04 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de mapk/erk kinase
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
ES2387707T3
(es)
|
2007-12-21 |
2012-09-28 |
Genentech, Inc. |
Azaindolizinas y procedimientos de uso
|
|
GB0801080D0
(en)
|
2008-01-21 |
2008-02-27 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB0801081D0
(en)
|
2008-01-21 |
2008-02-27 |
Ucb Pharma Sa |
Therapeutic agents
|
|
EP2240494B1
(fr)
|
2008-01-21 |
2016-03-30 |
UCB Biopharma SPRL |
Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
|
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
JP2012529535A
(ja)
|
2009-06-12 |
2012-11-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼモジュレーターとして有用なニコチンアミド化合物
|
|
DE102010012594A1
(de)
|
2010-03-23 |
2011-09-29 |
Beiersdorf Ag |
Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten
|
|
US9422262B2
(en)
|
2010-09-24 |
2016-08-23 |
The Broad Institute, Inc. |
Compounds and methods for treating diseases mediated by protease activated receptors
|
|
NZ608592A
(en)
|
2010-11-05 |
2015-08-28 |
Hoffmann La Roche |
Use of active pharmaceutical compounds for the treatment of central nervous system conditions
|
|
WO2012099968A1
(fr)
|
2011-01-19 |
2012-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions et procédés de traitement de maladies associées à un cancer de la peau
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
WO2012171484A1
(fr)
|
2011-06-17 |
2012-12-20 |
中国中化股份有限公司 |
Composés de cyanoaniline substitués, leur préparation et leur utilisation
|
|
WO2014179785A1
(fr)
|
2013-05-03 |
2014-11-06 |
Inscent, Inc. |
Répulsifs améliorés contre les abeilles domestiques et leurs utilisations
|
|
US10835513B2
(en)
|
2013-06-28 |
2020-11-17 |
The Regents Of The University Of California |
Methods and treatments for the learning and memory deficits associated with Noonan syndrome
|
|
US9572828B2
(en)
|
2013-07-18 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Treatment for melanoma
|
|
DK3290407T3
(da)
*
|
2013-10-18 |
2020-03-23 |
Celgene Quanticel Res Inc |
Bromodomæneinhibitorer
|
|
CN105384754B
(zh)
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
JP2018535238A
(ja)
|
2015-11-30 |
2018-11-29 |
イグナイタ インコーポレイテッド |
局所製剤
|
|
EP3301094A1
(fr)
|
2016-09-30 |
2018-04-04 |
Mutabilis |
Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes
|
|
DE102016225694A1
(de)
|
2016-12-21 |
2018-06-21 |
Robert Bosch Gmbh |
Verfahren zur Verstärkung der Bremskraft in einer elektronisch schlupfregelbaren Fahrzeugbremsanlage und elektronisch schlupfregelbare Fahrzeugbremsanlage
|
|
MA49141A
(fr)
|
2017-05-19 |
2020-03-25 |
Nflection Therapeutics Inc |
Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
|
|
CA3063535A1
(fr)
|
2017-05-19 |
2018-11-22 |
Nflection Therapeutics, Inc. |
Composes heteroaromatiques-aniline fusionnes pour le traitement de troubles dermiques
|
|
US11395823B2
(en)
|
2018-01-09 |
2022-07-26 |
Duke University |
Topical administration of MEK inhibiting agents for the treatment of skin disorders
|
|
WO2020101878A2
(fr)
|
2018-10-29 |
2020-05-22 |
The Johns Hopkins University |
Traitement de rasopathie
|
|
CA3120351A1
(fr)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau
|
|
US12378240B2
(en)
|
2018-11-20 |
2025-08-05 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
JP7546297B2
(ja)
|
2018-11-20 |
2024-09-06 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのチエニル－アニリン化合物
|
|
EP4233834A3
(fr)
|
2018-11-20 |
2023-10-25 |
NFlection Therapeutics, Inc. |
Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
|
|
WO2020106304A1
(fr)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Formulations topiques
|
|
MA55141A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés cyanoaryl-aniline pour le traitement d'affections de la peau
|
|
IL301496A
(en)
|
2020-09-24 |
2023-05-01 |
Nflection Therapeutics Inc |
Treatment of cognitive dysfunction with pyrrolopyridine-aniline compounds
|
|
EP4281055A4
(fr)
|
2021-01-21 |
2025-06-18 |
NFlection Therapeutics, Inc. |
Formes cristallines d'un composé de pyrrolopyridine-aniline
|
|
JP2024503893A
(ja)
|
2021-01-21 |
2024-01-29 |
エヌフレクション セラピューティクス インコーポレイテッド |
ピロロピリジン－アニリン化合物を調製するための方法
|